Sanos

Sanos

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.2M

Overview

Founded in 2016, Sanos has established itself as a specialized, full-service CRO focused on three core therapeutic niches: musculoskeletal, neurological, and dermatological conditions. The company differentiates itself through deep therapeutic expertise, a science-led approach, and an integrated operational model that includes proprietary research clinics and digital recruitment platforms. With a track record of over 0+ clinical trials and a stated high patient retention rate, Sanos positions itself as a strategic partner for biopharma companies seeking efficient, high-quality clinical development in its areas of specialization.

MusculoskeletalNeurologicalDermatological

Technology Platform

Integrated full-service CRO platform combining specialized therapeutic expertise (via NBCD, Neuroscios, Blueskin brands), digital patient recruitment analytics, proprietary research clinics (Sanos Clinic), eCOA solutions, end-to-end clinical trial supply (Sanos Supply), and advanced data science capabilities.

Funding History

1
Total raised:$6.2M
Seed$6.2M

Opportunities

Growing demand for specialized, therapeutic-area-expert CRO services in complex fields like neurology and dermatology presents a significant opportunity.
The industry shift towards decentralized/hybrid trials and digital data collection also plays to Sanos's strengths in eCOA, digital recruitment, and owned clinic networks.

Risk Factors

Faces intense competition from large global CROs and other niche players.
Its integrated model concentrates operational risk, and its financial health is tied to the R&D spending cycles within its three focused therapeutic areas, making it vulnerable to sector-specific downturns.

Competitive Landscape

Sanos competes in the crowded CRO market, differentiating itself through deep specialization in three therapeutic areas and an integrated service model. It competes against large, full-service global CROs on expertise and personal service, and against other niche CROs on its breadth of integrated, in-house capabilities.